{
    "clinical_study": {
        "@rank": "104369", 
        "arm_group": [
            {
                "arm_group_label": "13vPnC+SIIV/Placebo", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo+SIIV/13vPnC", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the immunogenicity and safety of 13-valent\n      pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated\n      influenza vaccine to adults 50 years and older who have previously received 23-valent\n      pneumococcal polysaccharide vaccine."
        }, 
        "brief_title": "Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Evidence of a personally signed and dated informed consent document (ICD) indicating\n             that the subject has been informed of all pertinent aspects of the study.\n\n          2. Male or female adults 50 years of age or older.\n\n          3. Documented vaccination with 1 or more prior doses of 23vPS, the last given at least 1\n             year prior to study enrollment.\n\n          4. Negative urine pregnancy test for all female subjects who are of child bearing\n             potential.\n\n        Exclusion Criteria:\n\n          1. Previous vaccination with Prevnar\u00ae, Prevnar 13\u00ae, or any other investigational\n             pneumococcal conjugate vaccine.\n\n          2. History of severe adverse reactions associated with any vaccine or vaccine-related\n             component.\n\n          3. Allergic to egg proteins (egg or egg products) and chicken proteins.\n\n          4. History of Guillain-Barr\u00e9 syndrome.\n\n          5. Vaccination with any influenza vaccine within 6 months (182 days) before\n             investigational product administration.\n\n          6. Documented S pneumoniae infection within the past 5 years before investigational\n             product administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "882", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124161", 
            "org_study_id": "B1851138"
        }, 
        "intervention": [
            {
                "arm_group_label": "13vPnC+SIIV/Placebo", 
                "description": "One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.", 
                "intervention_name": "13-valent pneumococcal conjugate vaccine", 
                "intervention_type": "Biological", 
                "other_name": "13vPnC"
            }, 
            {
                "arm_group_label": "13vPnC+SIIV/Placebo", 
                "description": "One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.", 
                "intervention_name": "Seasonal Inactivated Influenza Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "SIIV"
            }, 
            {
                "arm_group_label": "13vPnC+SIIV/Placebo", 
                "description": "One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo+SIIV/13vPnC", 
                "description": "One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo+SIIV/13vPnC", 
                "description": "One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.", 
                "intervention_name": "Seasonal Inactivated Influenza Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "SIIV"
            }, 
            {
                "arm_group_label": "Placebo+SIIV/13vPnC", 
                "description": "One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.", 
                "intervention_name": "13-valent pneumococcal conjugate vaccine", 
                "intervention_type": "Biological", 
                "other_name": "13vPnC"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pneumococcal polysaccharide vaccine", 
            "13-valent pneumococcal conjugate vaccine", 
            "invasive pneumococcal disease", 
            "flu vaccine"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851138&StudyName=Concomitant%20administration%20of%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20with%20influenza%20vaccine%20in%2023-valent%20Pneumococcal%20Polysaccharid"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 4, Randomized, Double-blind Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine in Adults 50 Years and Older Who Received 1 Or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine Prior to Study Enrollment.", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "The hemagglutination inhibition (HAI) geometric mean titers (GMTs) for each influenza virus strain in the SIIV", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "The number and proportion of subjects with adverse events (AEs) and serious adverse events (SAEs).", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The percentage of subjects achieving pneumococcal serotype-specific OPA titers greater than or equal to the lower limit of quantitation (LLOQ).", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "The pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs).", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "The proportion of subjects achieving seroconversion in HAI titers.", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "The HAI GMFRs for each influenza virus strain.", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}